BMO Upgraded Biogen (BIIB) Earlier Following Positive Data on BG-12
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $111.49 +0.69%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Biogen (NASDAQ: BIIB) were upgraded from Underperform to Market Perform at BMO Capital early this morning following news the company's BG-12 trial met the primary endpoint in two Phase II trials. The firm's price target was raised from $74 to $112.
Biogen shares are up more than 10 percent this afternoon.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Biogen shares are up more than 10 percent this afternoon.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
